Registry for Systemic Eczema Treatments (RESET)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Rebecca Urbonas, BS
- Phone Number: 813-300-1317
- Email: rurbona1@jh.edu
Study Contact Backup
- Name: Zeena Mestari, BA
- Phone Number: 1 (848) 702-4101
- Email: zmestar1@jh.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- Recruiting
- Johns Hopkins University
-
Principal Investigator:
- Joy Wan, MD MSCE
-
Contact:
- Zeena Mestari, BA
- Phone Number: 848-702-4101
- Email: Zmestar1@jh.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria:
- Age <26 years old
- Current physician diagnosis of atopic dermatitis
- Provide signed informed consent if ≥ 18 years old
- Provide signed informed consent by parent or legal guardian (if <18 years old) and informed assent if applicable
- Subject and/or parent/legal guardian is willing to be contacted in the future by study staff
- Seen for clinical care at Johns Hopkins since 1/1/2017
- Previously on, currently on, or planning to initiate (within next 6 months) a systemic AD therapy
Exclusion criteria:
- Age ≥26 years old at the time of registry enrollment
- Does not speak English
- If <18 years old, has a primary caretaker who does not speak English
- If <18 years old, parent/legal guardian is unwilling to sign the written informed consent
- Is a foster child
- Has not received clinical care at Johns Hopkins since 1/1/2017
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Methotrexate
Participants who have received methotrexate for atopic dermatitis.
|
|
Cyclosporine
Participants who have received cyclosporine for atopic dermatitis.
|
|
Mycophenolate mofetil
Participants who have received mycophenolate mofetil for atopic dermatitis.
|
|
Azathioprine
Participants who have received azathioprine for atopic dermatitis.
|
|
Dupilumab
Participants who have received dupilumab for atopic dermatitis.
|
|
Tralokinumab
Participants who have received tralokinumab for atopic dermatitis.
|
|
Upadacitinib
Participants who have received upadacitinib for atopic dermatitis.
|
|
Abrocitinib
Participants who have received abrocitinib for atopic dermatitis.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment effectiveness as assessed by the change in Investigator's Global Assessment (IGA) Scores
Time Frame: 3 years
|
To evaluate the clinical effectiveness of systemic treatments for atopic dermatitis according to IGA through periodic electronic medical record (EMR) review.
The IGA is a physician-reported atopic dermatitis severity score.
IGA is the global clinical assessment scale to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on the degree of erythema and papulation/infiltration.
The IGA score ranges from 0 to 4. Higher scores indicate greater severity of AD.
|
3 years
|
|
Treatment effectiveness as assessed by the change in Eczema Area and Severity Index (EASI) Scores
Time Frame: 3 years
|
To evaluate the clinical effectiveness of systemic treatments for atopic dermatitis according to EASI through periodic electronic medical record (EMR) review.
The EASI score is a physician-reported atopic dermatitis severity score.
EASI is used to evaluate severity of AD based on AD clinical signs and % of body surface area (BSA) affected.
Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) is scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe.
The total EASI score ranges from 0 to 72.
Higher scores indicate greater severity of AD.
|
3 years
|
|
Treatment effectiveness as assessed by the change in Patient Oriented Eczema Measure (POEM) Scores
Time Frame: Quarterly from baseline to 3 years
|
To evaluate the effectiveness of systemic treatments for atopic dermatitis (AD) according to a POEM score.
The POEM score is a patient-reported AD severity score.
The POEM is a 7-item questionnaire to assess disease symptoms in children and adults with AD.
It is composed of 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on symptom frequency during the past week (0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day').
The total POEM score ranges from 0 to 28.
Higher scores indicate more severe disease and poor quality of life.
|
Quarterly from baseline to 3 years
|
|
Treatment effectiveness as assessed by the change in Patient-Reported Outcomes Measurement Information System (PROMIS) Itch questionnaire score
Time Frame: Quarterly from baseline to 3 years
|
To evaluate the effectiveness of systemic treatments for atopic dermatitis (AD) according to the PROMIS Itch questionnaire.
The PROMIS Itch questionnaire measures the extent to which patients experience problems with itchiness over the past 7 days using a 5-point Likert scale (1 = Never; 2 = Rarely; 3 = Sometimes; 4 = Often; and 5 = Almost Always).
Higher scores reflect greater severity of experienced itch symptoms.
|
Quarterly from baseline to 3 years
|
|
Treatment effectiveness as assessed by the change in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety questionnaire score
Time Frame: Quarterly from baseline to 3 years
|
To evaluate the effectiveness of systemic treatments for atopic dermatitis (AD) according to the PROMIS Anxiety questionnaire.
The PROMIS Anxiety questionnaire measures the extent to which patients experience problems with anxiety over the past 7 days using a 5-point Likert scale (1 = Never; 2 = Almost never; 3 = Sometimes; 4 = Often; and 5 = Almost Always).
The questionnaire includes fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), social/separation anxiety (fear or distress when separating from caregivers), and somatic symptoms related to arousal (racing heart, dizziness).
Higher scores reflect greater severity of experienced anxiety symptoms.
|
Quarterly from baseline to 3 years
|
|
Treatment effectiveness as assessed by the change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Problem questionnaire score
Time Frame: Quarterly from baseline to 3 years
|
To evaluate the effectiveness of systemic treatments for atopic dermatitis (AD) according to the PROMIS Sleep Problem/Health questionnaires.
The PROMIS Sleep Problem questionnaire measures the extent to which patients experience problems with sleep over the past 7 days using a 5-point Likert scale (1 = Never; 2 = Almost never; 3 = Sometimes; 4 = Almost always; and 5 = Always).
The sleep problems contain sleep disturbances (sleep quality, sleep onset, sleep continuity) and sleep-related impairment (perceptions of sleepiness during usual awake hours and reported impairments during the day associated with sleep problems or daytime sleepiness).
Higher scores reflect greater severity of sleep problems.
|
Quarterly from baseline to 3 years
|
|
Treatment effectiveness as assessed by the change in Patient-Reported Outcomes Measurement Information System (PROMIS) Depressive Symptoms questionnaire score
Time Frame: Quarterly from baseline to 3 years
|
To evaluate the effectiveness of systemic treatments for atopic dermatitis (AD) according to the PROMIS Depressive Symptoms questionnaire.
The PROMIS Depressive Symptoms questionnaire measures the extent to which patients experience problems with depression over the past 7 days using a 5-point Likert scale (1 = Never; 2 = Almost never; 3 = Sometimes; 4 = Almost Always; and 5 = Always).
The depressive symptoms include negative mood (sadness, guilt), views of self (self-criticism, worthlessness), and social cognition (loneliness, interpersonal alienation); decreased positive affect, anhedonia (loss of interest, inability to engage in play), and engagement.
Higher scores reflect greater severity of experienced depressive symptoms.
|
Quarterly from baseline to 3 years
|
|
Treatment effectiveness as assessed by the change in Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function questionnaire score
Time Frame: Quarterly from baseline to 3 years
|
To evaluate the effectiveness of systemic treatments for atopic dermatitis (AD) according to the PROMIS Cognitive Function questionnaire.
The PROMIS Cognitive Function questionnaire measures the extent to which patients experience problems with cognitive function over the past 4 weeks using a 5-point Likert scale (1 = All of the time; 2 = Most of the time; 3 = Some of the time; 4 = A little of the time; and 5 = None of the time).
The questionnaire includes difficulties in cognitive abilities (e.g., memory, attention, and decision making), and difficulties in the application of such abilities to everyday tasks (e.g., planning, organizing, calculating, remembering, and learning).
Lower scores reflect greater impact on cognitive function.
|
Quarterly from baseline to 3 years
|
|
Treatment effectiveness as assessed by the change in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health questionnaire score
Time Frame: Quarterly from baseline to 3 years
|
To evaluate the effectiveness of systemic treatments for atopic dermatitis (AD) according to the PROMIS Global Health questionnaire.
The PROMIS Global Health questionnaire measures the extent to which patients experience problems with global health in general using a 5-point Likert scale (1 = Poor; 2 = Fair; 3 = Good; 4 = Fair; and 5 = Excellent).
The questionnaire includes an overall evaluation of physical, mental health, and social health.
Higher scores reflect a lower quality of global health.
|
Quarterly from baseline to 3 years
|
|
Treatment effectiveness as assessed by the change in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity questionnaire score
Time Frame: Quarterly from baseline to 3 years
|
To evaluate the effectiveness of systemic treatments for atopic dermatitis (AD) according to the PROMIS Pain Intensity questionnaire.
The PROMIS Pain Intensity questionnaire measures the intensity of patients' pain due to their AD over the past 7 days using a 10 point scale, with 0 indicating "No Pain" and 10 indicating "the worst pain possible."
Higher raw scores reflect greater severity of experienced pain due to AD.
|
Quarterly from baseline to 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of discontinuation or dose de-escalation of systemic treatment
Time Frame: 3 years
|
To assess rates of discontinuation or dose de-escalation per systemic treatment (e.g.
dupilumab, tralokinumab, upadacitinib and abrocitinib) in patients with well-controlled atopic dermatitis
|
3 years
|
|
Adverse effects of systemic treatments for atopic dermatitis
Time Frame: 3 years
|
To collect data on adverse effects of systemic treatments for AD (e.g.
conjunctivitis, injection site reaction, renal or liver impairment, cardiovascular events, malignancy, infection, etc.) to assess the safety of each systemic treatment.
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Joy Wan, MD MSCE, Johns Hopkins University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00372852
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.